1. Home
  2. WEAV vs VNDA Comparison

WEAV vs VNDA Comparison

Compare WEAV & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weave Communications Inc.

WEAV

Weave Communications Inc.

HOLD

Current Price

$6.84

Market Cap

524.3M

Sector

Technology

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$8.06

Market Cap

441.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEAV
VNDA
Founded
2011
2002
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
524.3M
441.5M
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
WEAV
VNDA
Price
$6.84
$8.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$12.20
$13.63
AVG Volume (30 Days)
1.4M
2.7M
Earning Date
02-19-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$229,790,000.00
$212,074,000.00
Revenue This Year
$19.22
$12.01
Revenue Next Year
$15.10
$24.28
P/E Ratio
N/A
N/A
Revenue Growth
17.34
11.12
52 Week Low
$5.64
$3.81
52 Week High
$17.63
$9.60

Technical Indicators

Market Signals
Indicator
WEAV
VNDA
Relative Strength Index (RSI) 48.06 60.98
Support Level $6.48 $7.14
Resistance Level $7.32 $7.82
Average True Range (ATR) 0.30 0.41
MACD -0.06 -0.04
Stochastic Oscillator 30.20 68.29

Price Performance

Historical Comparison
WEAV
VNDA

About WEAV Weave Communications Inc.

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: